



## Clinical trial results:

### A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer

#### Summary

EudraCT number	2011-002913-12
Trial protocol	CZ HU DK SK FI SE BE NL ES
Global end of trial date	02 September 2020

#### Results information

Result version number	v1 (current)
This version publication date	27 August 2021
First version publication date	27 August 2021

#### Trial information

##### Trial identification

Sponsor protocol code	M12-895
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01506609
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	AbbVie
Sponsor organisation address	AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, United States, SL6 4UB
Public contact	Global Medical Services, AbbVie, AbbVie, 001 8006339110, <a href="mailto:abbvieclinicaltrials@abbvie.com">abbvieclinicaltrials@abbvie.com</a>
Scientific contact	Global Medical Services, AbbVie, AbbVie, 001 8006339110, <a href="mailto:abbvieclinicaltrials@abbvie.com">abbvieclinicaltrials@abbvie.com</a>

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	02 September 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	02 September 2020
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of the study is to assess the progression-free survival (PFS) of oral veliparib in combination with TMZ or in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in subjects with Breast Cancer Gene (BRCA)1 or BRCA2 mutation and locally recurrent or metastatic breast cancer.

Protection of trial subjects:

Subject and/or legal guardian read and understood the information provided about the study and gave written permission.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	23 January 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 6
Country: Number of subjects enrolled	Australia: 14
Country: Number of subjects enrolled	Belgium: 12
Country: Number of subjects enrolled	Brazil: 4
Country: Number of subjects enrolled	Canada: 17
Country: Number of subjects enrolled	Czechia: 12
Country: Number of subjects enrolled	Denmark: 9
Country: Number of subjects enrolled	Finland: 2
Country: Number of subjects enrolled	France: 36
Country: Number of subjects enrolled	Hungary: 7
Country: Number of subjects enrolled	Israel: 9
Country: Number of subjects enrolled	Netherlands: 8
Country: Number of subjects enrolled	Norway: 1
Country: Number of subjects enrolled	Poland: 7
Country: Number of subjects enrolled	Romania: 1
Country: Number of subjects enrolled	Russian Federation: 5
Country: Number of subjects enrolled	Spain: 9
Country: Number of subjects enrolled	Sweden: 5
Country: Number of subjects enrolled	Ukraine: 20

Country: Number of subjects enrolled	United States: 110
Worldwide total number of subjects	294
EEA total number of subjects	109

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	283
From 65 to 84 years	11
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Under the original protocol, approximately 4 participants were randomized in a 1:1:1 ratio (Group 1) to 1 of the 3 treatment arms at approximately 3 research sites. Participants randomized under the original protocol were in Group 1, and were not included in the primary efficacy analyses.

### Pre-assignment

Screening details:

Following approval of Amendment 1, the veliparib dose in combination with carboplatin + paclitaxel was increased to 120 mg BID. Participants were randomized 1:1:1 ratio (Group 2) to 1 of the 3 treatment arms at approximately 120 sites. Participants randomized following Amendment 1 approval were in Group 2 and included in primary efficacy analyses.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject

Blinding implementation details:

This is a partially blinded study. AbbVie, the investigator, the study site personnel, and the subject remained blinded to each subject's treatment with veliparib or placebo in the carboplatin + paclitaxel arms throughout the course of the study. All subjects randomized to the veliparib + TMZ treatment arm were treated in an open-label fashion.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Group 1 Placebo + Carboplatin/ Paclitaxel

Arm description:

Placebo BID Days 1 through 7 plus carboplatin target area under the curve (mg•min/mL) (AUC) 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m<sup>2</sup> administered on Day 3 of each 21-day cycle.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects self-administer the morning dose of placebo and the evening dose placebo approximately 12 hours after the morning dose with or without food in the same calendar day for Days 1 through 7 of the 21-day cycle.

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Carboplatin will be administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.

Investigational medicinal product name	Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion

Routes of administration	Intravenous use
--------------------------	-----------------

Dosage and administration details:

Paclitaxel will be administered intravenously over approximately 3 hours at a dose of 175 mg/m<sup>2</sup>.

<b>Arm title</b>	Group 1 Veliparib + Carboplatin/ Paclitaxel
------------------	---

Arm description:

Veliparib 80 mg BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m<sup>2</sup> administered on Day 3 of each 21-day cycle.

Arm type	Experimental
Investigational medicinal product name	Veliparib
Investigational medicinal product code	ABT-888
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects will self-administer the morning dose of veliparib and the evening dose of veliparib approximately 12 hours after the morning dose with or without food in the same calendar day for Days 1 through 7 of the 21-day cycle.

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Carboplatin will be administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.

Investigational medicinal product name	Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Paclitaxel will be administered intravenously over approximately 3 hours at a dose of 175 mg/m<sup>2</sup>.

<b>Arm title</b>	Group 1 Veliparib + TMZ
------------------	-------------------------

Arm description:

Veliparib 40 mg BID Days 1 through 7 plus TMZ 150 to 200 mg/m<sup>2</sup> QD Days 1 through 5 in each 28-day cycle.

Arm type	Experimental
Investigational medicinal product name	Temozolomide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects will self-administer the morning dose of veliparib and TMZ at the same time under fasting conditions (to reduce the chance of nausea and vomiting per the TMZ label recommendation) and the evening doses of veliparib approximately 12 hours after the morning dose with or without food in the same calendar day.

Investigational medicinal product name	Veliparib
Investigational medicinal product code	ABT-888
Other name	
Pharmaceutical forms	Capsule

Routes of administration	Oral use
Dosage and administration details: Subjects will self-administer the morning dose of veliparib and TMZ at the same time under fasting conditions (to reduce the chance of nausea and vomiting per the TMZ label recommendation) and the evening doses of veliparib approximately 12 hours after the morning dose with or without food in the same calendar day.	
<b>Arm title</b>	Group 2 Placebo + Carboplatin/ Paclitaxel
Arm description: Placebo BID Days 1 through 7 plus carboplatin carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m <sup>2</sup> administered on Day 3 of each 21-day cycle.	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details: Subjects self-administer the morning dose of placebo and the evening dose placebo approximately 12 hours after the morning dose with or without food in the same calendar day for Days 1 through 7 of the 21-day cycle.	
Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use
Dosage and administration details: Carboplatin will be administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.	
Investigational medicinal product name	Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use
Dosage and administration details: Paclitaxel will be administered intravenously over approximately 3 hours at a dose of 175 mg/m <sup>2</sup> .	
<b>Arm title</b>	Group 2 Veliparib + Carboplatin/ Paclitaxel
Arm description: Veliparib 120 mg BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m <sup>2</sup> administered on Day 3 of each 21-day cycle.	
Arm type	Experimental
Investigational medicinal product name	Veliparib
Investigational medicinal product code	ABT-888
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details: Subjects will self-administer the morning dose of veliparib and the evening dose of veliparib approximately 12 hours after the morning dose with or without food in the same calendar day for Days 1 through 7 of the 21-day cycle.	
Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Carboplatin will be administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.

Investigational medicinal product name	Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Paclitaxel will be administered intravenously over approximately 3 hours at a dose of 175 mg/m<sup>2</sup>.

<b>Arm title</b>	Group 2 Veliparib + TMZ
------------------	-------------------------

Arm description:

Veliparib 40 mg BID Days 1 through 7 plus TMZ 150 to 200 mg/m<sup>2</sup> QD Days 1 through 5 in each 28-day cycle.

Arm type	Experimental
Investigational medicinal product name	Temozolomide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects will self-administer the morning dose of veliparib and TMZ at the same time under fasting conditions (to reduce the chance of nausea and vomiting per the TMZ label recommendation) and the evening doses of veliparib approximately 12 hours after the morning dose with or without food in the same calendar day.

Investigational medicinal product name	Veliparib
Investigational medicinal product code	ABT-888
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects will self-administer the morning dose of veliparib and TMZ at the same time under fasting conditions (to reduce the chance of nausea and vomiting per the TMZ label recommendation) and the evening doses of veliparib approximately 12 hours after the morning dose with or without food in the same calendar day.

<b>Number of subjects in period 1</b>	Group 1 Placebo + Carboplatin/ Paclitaxel	Group 1 Veliparib + Carboplatin/ Paclitaxel	Group 1 Veliparib + TMZ
Started	2	1	1
Completed	0	0	0
Not completed	2	1	1
Adverse Event Related to Progression	-	-	-
Consent withdrawn by subject	-	-	-
Missing / Unknown Reason	1	-	1
Progressive Disease per Protocol	1	-	-
Sponsor Discontinued Study	-	-	-
Adverse Event Not Related to Progression	-	1	-

Lost to follow-up	-	-	-
Other, Not Specified	-	-	-

Number of subjects in period 1	Group 2 Placebo + Carboplatin/ Paclitaxel	Group 2 Veliparib + Carboplatin/ Paclitaxel	Group 2 Veliparib + TMZ
Started	99	97	94
Completed	0	1	0
Not completed	99	96	94
Adverse Event Related to Progression	3	7	3
Consent withdrawn by subject	9	7	7
Missing / Unknown Reason	4	4	2
Progressive Disease per Protocol	64	57	74
Sponsor Discontinued Study	2	2	-
Adverse Event Not Related to Progression	6	10	5
Lost to follow-up	1	2	-
Other, Not Specified	10	7	3



## Baseline characteristics

### Reporting groups

Reporting group title	Group 1 Placebo + Carboplatin/ Paclitaxel
Reporting group description: Placebo BID Days 1 through 7 plus carboplatin target area under the curve (mg•min/mL) (AUC) 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m <sup>2</sup> administered on Day 3 of each 21-day cycle.	
Reporting group title	Group 1 Veliparib + Carboplatin/ Paclitaxel
Reporting group description: Veliparib 80 mg BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m <sup>2</sup> administered on Day 3 of each 21-day cycle.	
Reporting group title	Group 1 Veliparib + TMZ
Reporting group description: Veliparib 40 mg BID Days 1 through 7 plus TMZ 150 to 200 mg/m <sup>2</sup> QD Days 1 through 5 in each 28-day cycle.	
Reporting group title	Group 2 Placebo + Carboplatin/ Paclitaxel
Reporting group description: Placebo BID Days 1 through 7 plus carboplatin carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m <sup>2</sup> administered on Day 3 of each 21-day cycle.	
Reporting group title	Group 2 Veliparib + Carboplatin/ Paclitaxel
Reporting group description: Veliparib 120 mg BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m <sup>2</sup> administered on Day 3 of each 21-day cycle.	
Reporting group title	Group 2 Veliparib + TMZ
Reporting group description: Veliparib 40 mg BID Days 1 through 7 plus TMZ 150 to 200 mg/m <sup>2</sup> QD Days 1 through 5 in each 28-day cycle.	

Reporting group values	Group 1 Placebo + Carboplatin/ Paclitaxel	Group 1 Veliparib + Carboplatin/ Paclitaxel	Group 1 Veliparib + TMZ
Number of subjects	2	1	1
Age categorical			
Units: Subjects			
< 45 years	2	1	0
45 to 64 years	0	0	1
>= 65 years	0	0	0
Gender categorical			
Units: Subjects			
Female	2	1	1
Male	0	0	0
Ethnicity			
Units: Subjects			
Hispanic or Latino	0	0	0
No Ethnicity	2	1	1
Race			
Units: Subjects			
White	2	1	1
Black	0	0	0
Asian	0	0	0

Native Hawaiian or Other Pacific Islander	0	0	0
Other, Not Specified	0	0	0

<b>Reporting group values</b>	Group 2 Placebo + Carboplatin/ Paclitaxel	Group 2 Veliparib + Carboplatin/ Paclitaxel	Group 2 Veliparib + TMZ
Number of subjects	99	97	94
Age categorical Units: Subjects			
< 45 years	47	49	41
45 to 64 years	49	47	46
>= 65 years	3	1	7
Gender categorical Units: Subjects			
Female	97	95	92
Male	2	2	2
Ethnicity Units: Subjects			
Hispanic or Latino	6	7	5
No Ethnicity	93	90	89
Race Units: Subjects			
White	93	92	83
Black	4	3	10
Asian	0	1	1
Native Hawaiian or Other Pacific Islander	0	1	0
Other, Not Specified	2	0	0

<b>Reporting group values</b>	Total		
Number of subjects	294		
Age categorical Units: Subjects			
< 45 years	140		
45 to 64 years	143		
>= 65 years	11		
Gender categorical Units: Subjects			
Female	288		
Male	6		
Ethnicity Units: Subjects			
Hispanic or Latino	18		
No Ethnicity	276		
Race Units: Subjects			
White	272		
Black	17		
Asian	2		
Native Hawaiian or Other Pacific Islander	1		

Other, Not Specified	2		
----------------------	---	--	--

## End points

### End points reporting groups

Reporting group title	Group 1 Placebo + Carboplatin/ Paclitaxel
Reporting group description: Placebo BID Days 1 through 7 plus carboplatin target area under the curve (mg•min/mL) (AUC) 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m <sup>2</sup> administered on Day 3 of each 21-day cycle.	
Reporting group title	Group 1 Veliparib + Carboplatin/ Paclitaxel
Reporting group description: Veliparib 80 mg BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m <sup>2</sup> administered on Day 3 of each 21-day cycle.	
Reporting group title	Group 1 Veliparib + TMZ
Reporting group description: Veliparib 40 mg BID Days 1 through 7 plus TMZ 150 to 200 mg/m <sup>2</sup> QD Days 1 through 5 in each 28-day cycle.	
Reporting group title	Group 2 Placebo + Carboplatin/ Paclitaxel
Reporting group description: Placebo BID Days 1 through 7 plus carboplatin carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m <sup>2</sup> administered on Day 3 of each 21-day cycle.	
Reporting group title	Group 2 Veliparib + Carboplatin/ Paclitaxel
Reporting group description: Veliparib 120 mg BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m <sup>2</sup> administered on Day 3 of each 21-day cycle.	
Reporting group title	Group 2 Veliparib + TMZ
Reporting group description: Veliparib 40 mg BID Days 1 through 7 plus TMZ 150 to 200 mg/m <sup>2</sup> QD Days 1 through 5 in each 28-day cycle.	

### Primary: Progression-Free Survival (PFS)

End point title	Progression-Free Survival (PFS) <sup>[1]</sup>
End point description: PFS is defined as the number of months from the date the participant was randomized to the date of radiographic progression as determined by the central imaging center, or to the date of all cause deaths within 63 days of last tumor assessment if disease progression was not reached.  Group 2: All randomized participants with suspected deleterious or deleterious BRCA1 or BRCA2 mutation determined by sponsor core lab.	
End point type	Primary
End point timeframe: Radiographic evaluation every 9 weeks, clinical evaluation every cycle (data cutoff date: 04 March 2016); maximum duration of follow up for PFS was 34 months.	

#### Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: Group 2 was used for all efficacy analyses per protocol.

<b>End point values</b>	Group 2 Placebo + Carboplatin/ Paclitaxel	Group 2 Veliparib + Carboplatin/ Paclitaxel	Group 2 Veliparib + TMZ	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	98	95	91	
Units: months				
median (confidence interval 95%)	12.3 (9.3 to 14.5)	14.1 (11.5 to 16.2)	7.4 (5.9 to 8.5)	

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Comparison groups	Group 2 Placebo + Carboplatin/ Paclitaxel v Group 2 Veliparib + Carboplatin/ Paclitaxel
Number of subjects included in analysis	193
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.227
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.789
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.536
upper limit	1.162

<b>Statistical analysis title</b>	Statistical Analysis 2
Comparison groups	Group 2 Placebo + Carboplatin/ Paclitaxel v Group 2 Veliparib + TMZ
Number of subjects included in analysis	189
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.858
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.278
upper limit	2.702

## Secondary: Overall Survival (OS)

End point title	Overall Survival (OS) <sup>[2]</sup>
-----------------	--------------------------------------

**End point description:**

Time to death for a given participant was defined as the number of months from the day the participant is randomized to the date of the participant's death. All events of death were included, regardless of whether the event occurs while the participant was still taking study drug, or after the participant discontinued study drug. If a participant had not died, then the data will be censored at the date when the participant was last known to be alive.

Group 2: All randomized participants with suspected deleterious or deleterious BRCA1 or BRCA2 mutation determined by sponsor core lab.

End point type	Secondary
----------------	-----------

**End point timeframe:**

From Cycle 1 Day 1 until participant's death or 3 years post discontinuation (data cutoff date: 04 March 2016); maximum duration of follow up for OS was 72 months.

**Notes:**

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Group 2 was used for all efficacy analyses per protocol.

<b>End point values</b>	Group 2 Placebo + Carboplatin/ Paclitaxel	Group 2 Veliparib + Carboplatin/ Paclitaxel	Group 2 Veliparib + TMZ	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	98	95	91	
Units: months				
median (confidence interval 95%)	25.4 (18.3 to 32.1)	28.3 (24.9 to 33.4)	19.1 (14.3 to 21.3)	

**Statistical analyses**

<b>Statistical analysis title</b>	Statistical Analysis 1
Comparison groups	Group 2 Placebo + Carboplatin/ Paclitaxel v Group 2 Veliparib + Carboplatin/ Paclitaxel
Number of subjects included in analysis	193
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.368
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.848
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.59
upper limit	1.218

<b>Statistical analysis title</b>	Statistical Analysis 2
Comparison groups	Group 2 Placebo + Carboplatin/ Paclitaxel v Group 2 Veliparib + TMZ

Number of subjects included in analysis	189
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.017
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.512
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.074
upper limit	2.127

## Secondary: Clinical Benefit Rate (CBR) at Week 18

End point title	Clinical Benefit Rate (CBR) at Week 18 <sup>[3]</sup>
-----------------	---

End point description:

CBR: percentage of participants who were progression-free at 18 weeks, defined as complete response (CR), partial response (PR), stable disease (SD) or non-CR/non-disease progression (PD) per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1.

CR: The disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 0 mm. PR:  $\geq$  30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters (SOD). PD:  $\geq$  20% increase in the SOD of target lesions, taking as reference the smallest SOD recorded since the treatment started (baseline or after) or the appearance of  $\geq$  1 new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD since the treatment started (baseline or after).

End point type	Secondary
----------------	-----------

End point timeframe:

Week 18

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Group 2 was used for all efficacy analyses per protocol.

End point values	Group 2 Placebo + Carboplatin/ Paclitaxel	Group 2 Veliparib + Carboplatin/ Paclitaxel	Group 2 Veliparib + TMZ	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	98	95	91	
Units: percentage of participants				
number (confidence interval 95%)	87.0 (78.3 to 92.4)	90.7 (82.2 to 95.2)	73.0 (62.2 to 81.2)	

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Group 2 Placebo + Carboplatin/ Paclitaxel v Group 2 Veliparib + Carboplatin/ Paclitaxel

Number of subjects included in analysis	193
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.434 <sup>[4]</sup>
Method	Cochran-Mantel-Haenszel

Notes:

[4] - P-value is from Cochran-Mantel-Haenszel test stratified by estrogen receptor/progesterone receptor status and prior cytotoxic therapy use.

<b>Statistical analysis title</b>	Statistical Analysis 2
Comparison groups	Group 2 Placebo + Carboplatin/ Paclitaxel v Group 2 Veliparib + TMZ
Number of subjects included in analysis	189
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.019 <sup>[5]</sup>
Method	Cochran-Mantel-Haenszel

Notes:

[5] - P-value is from Cochran-Mantel-Haenszel test stratified by estrogen receptor/progesterone receptor status and prior cytotoxic therapy use.

## Secondary: Objective Response Rate (ORR)

End point title	Objective Response Rate (ORR) <sup>[6]</sup>
-----------------	--

End point description:

The objective response rate, defined as percentage of participants with a confirmed CR or PR based on RECIST 1.1 criteria. CR: The disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 0 mm. PR: ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline SODs.

Group 2: All randomized participants with suspected deleterious or deleterious BRCA1 or BRCA2 mutation determined by sponsor core lab. Participants with at least 1 measurable lesion at baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Radiographic evaluation every 9 weeks, clinical evaluation every cycle (data cutoff date: 04 March 2016); maximum duration of follow up for ORR was 34 months.

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Group 2 was used for all efficacy analyses per protocol.

End point values	Group 2 Placebo + Carboplatin/ Paclitaxel	Group 2 Veliparib + Carboplatin/ Paclitaxel	Group 2 Veliparib + TMZ	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	80	72	70	
Units: percentage of participants				
number (confidence interval 95%)	61.3 (49.7 to 71.9)	77.8 (66.4 to 86.7)	28.6 (18.4 to 40.6)	

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Comparison groups	Group 2 Placebo + Carboplatin/ Paclitaxel v Group 2 Veliparib



	+ Carboplatin/ Paclitaxel
Number of subjects included in analysis	152
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.027 <sup>[7]</sup>
Method	Cochran-Mantel-Haenszel

Notes:

[7] - P-value is from Cochran-Mantel-Haenszel test stratified by estrogen receptor/progesterone receptor status and prior cytotoxic therapy use.

<b>Statistical analysis title</b>	Statistical Analysis 2
Comparison groups	Group 2 Placebo + Carboplatin/ Paclitaxel v Group 2 Veliparib + TMZ
Number of subjects included in analysis	150
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 <sup>[8]</sup>
Method	Cochran-Mantel-Haenszel

Notes:

[8] - P-value is from Cochran-Mantel-Haenszel test stratified by estrogen receptor/progesterone receptor status and prior cytotoxic therapy use.

### **Secondary: Change From Baseline at Week 18 in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy Module (EORTC QLQ-CIPN20) Sensory Subscale Score**

End point title	Change From Baseline at Week 18 in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy Module (EORTC QLQ-CIPN20) Sensory Subscale Score <sup>[9]</sup>
-----------------	--

End point description:

EORTC QLQ-CIPN20 sensory subscale score was calculated following the standard scoring algorithm, transformed to a 0 (low quality of life) to 100 (best quality of life) scale. A positive change from baseline indicates improvement.

Group 2: All randomized participants with suspected deleterious or deleterious BRCA1 or BRCA2 mutation determined by sponsor core lab. Participants with a baseline and post baseline value. Per protocol, this outcome measure was not planned for the Veliparib + TMZ arm.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 18

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Group 2 was used for all efficacy analyses per protocol. No analysis was planned for the Velparib + TMZ arm for this endpoint per protocol.

<b>End point values</b>	Group 2 Placebo + Carboplatin/ Paclitaxel	Group 2 Veliparib + Carboplatin/ Paclitaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	62	69		
Units: score on a scale				
arithmetic mean (standard deviation)	13.94 (± 14.123)	11.24 (± 13.954)		

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Comparison groups	Group 2 Veliparib + Carboplatin/ Paclitaxel v Group 2 Placebo + Carboplatin/ Paclitaxel
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.354 <sup>[10]</sup>
Method	ANCOVA
Parameter estimate	Least Squares (LS) Mean of Difference
Point estimate	-2.302
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.2
upper limit	2.6
Variability estimate	Standard error of the mean
Dispersion value	2.476

Notes:

[10] - ANCOVA with treatment arm and baseline value as covariate.

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug up to 30 days after last dose of study drug. Median duration of treatment for Placebo + Carboplatin/Paclitaxel, Veliparib + Carboplatin/Paclitaxel, and Veliparib + TMZ arms were 70 days, 84 days, and 42 days, respectively.

Adverse event reporting additional description:

As Treated population: all randomized participants who took at least 1 dose of study drug (veliparib/placebo), analyzed by the actual treatment that participant received.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.1
--------------------	------

### Reporting groups

Reporting group title	Group 1 Placebo + Carboplatin/ Paclitaxel
-----------------------	---

Reporting group description:

Placebo BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m<sup>2</sup> administered on Day 3 of each 21-day cycle.

Reporting group title	Group 1 Veliparib + Carboplatin/Paclitaxel
-----------------------	--

Reporting group description:

Veliparib 80 mg BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m<sup>2</sup> administered on Day 3 of each 21-day cycle.

Reporting group title	Group 1 Veliparib + TMZ
-----------------------	-------------------------

Reporting group description:

Veliparib 40 mg BID Days 1 through 7 plus TMZ 150 to 200 mg/m<sup>2</sup> QD Days 1 through 5 in each 28-day cycle.

Reporting group title	Group 2 Placebo + Carboplatin/Paclitaxel
-----------------------	--

Reporting group description:

Placebo BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m<sup>2</sup> administered on Day 3 of each 21-day cycle.

Reporting group title	Group 2 Veliparib + Carboplatin/Paclitaxel
-----------------------	--

Reporting group description:

Veliparib 120 mg BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m<sup>2</sup> administered on Day 3 of each 21-day cycle.

Reporting group title	Group 2 Veliparib + TMZ
-----------------------	-------------------------

Reporting group description:

Veliparib 40 mg BID Days 1 through 7 plus TMZ 150 to 200 mg/m<sup>2</sup> QD Days 1 through 5 in each 28-day cycle.

Serious adverse events	Group 1 Placebo + Carboplatin/ Paclitaxel	Group 1 Veliparib + Carboplatin/Paclitaxel	Group 1 Veliparib + TMZ
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
number of deaths (all causes)	2	1	1
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

BREAST CANCER METASTATIC			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CANCER PAIN			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MALIGNANT NEOPLASM PROGRESSION			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
THROMBOPHLEBITIS SUPERFICIAL			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
ASTHENIA			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DISEASE PROGRESSION			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FATIGUE			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PYREXIA			

subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SUDDEN DEATH			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
DRUG HYPERSENSITIVITY			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
DYSпноEA			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
EPISTAXIS			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLEURAL EFFUSION			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMOTHORAX			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY EMBOLISM			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Psychiatric disorders			
ANXIETY			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MENTAL STATUS CHANGES			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
BLOOD CREATININE INCREASED			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
EJECTION FRACTION DECREASED			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OXYGEN SATURATION DECREASED			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
FEMORAL NECK FRACTURE			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEMUR FRACTURE			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PROCEDURAL HYPOTENSION			

subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RECALL PHENOMENON			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
THORACIC VERTEBRAL FRACTURE			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
ATRIAL FIBRILLATION			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC TAMPONADE			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PERICARDIAL EFFUSION			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TACHYCARDIA			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
CENTRAL NERVOUS SYSTEM LESION			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HAEMORRHAGE INTRACRANIAL			

subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEADACHE			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEIZURE			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SYNCOPE			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VOCAL CORD PARALYSIS			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEBRILE NEUTROPENIA			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LYMPHADENOPATHY			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEUTROPENIA			



subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>PANCYTOPENIA</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>THROMBOCYTOPENIA</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
<b>ABDOMINAL PAIN</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>ABDOMINAL PAIN UPPER</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>DIARRHOEA</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>NAUSEA</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>VOMITING</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hepatobiliary disorders</b>			

BILE DUCT OBSTRUCTION	subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEPATOTOXICITY	subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders				
URINARY RETENTION	subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders				
BONE PAIN	subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NECK PAIN	subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PATHOLOGICAL FRACTURE	subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations				
BACTERAEMIA	subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BETA HAEMOLYTIC STREPTOCOCCAL INFECTION				

subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>BREAST CELLULITIS</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>DEVICE RELATED INFECTION</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>DIVERTICULITIS</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>EMPHYSEMA</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>GASTROENTERITIS</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HERPES ZOSTER</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>MASTITIS</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>OTITIS MEDIA</b>			

subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>PNEUMONIA</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>PYELONEPHRITIS</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>SEPSIS</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>URINARY TRACT INFECTION</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>VIRAL UPPER RESPIRATORY TRACT INFECTION</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
<b>DEHYDRATION</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HYPOCALCAEMIA</b>			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Group 2 Placebo + Carboplatin/Paclitaxel	Group 2 Veliparib + Carboplatin/Paclitaxel	Group 2 Veliparib + TMZ
Total subjects affected by serious adverse events			
subjects affected / exposed	26 / 96 (27.08%)	32 / 93 (34.41%)	16 / 93 (17.20%)
number of deaths (all causes)	64	58	76
number of deaths resulting from adverse events	2	3	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BREAST CANCER METASTATIC			
subjects affected / exposed	2 / 96 (2.08%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
CANCER PAIN			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MALIGNANT NEOPLASM PROGRESSION			
subjects affected / exposed	0 / 96 (0.00%)	5 / 93 (5.38%)	4 / 93 (4.30%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 1
Vascular disorders			
THROMBOPHLEBITIS SUPERFICIAL			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
ASTHENIA			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DISEASE PROGRESSION			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FATIGUE			

subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PYREXIA			
subjects affected / exposed	2 / 96 (2.08%)	4 / 93 (4.30%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SUDDEN DEATH			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Immune system disorders			
DRUG HYPERSENSITIVITY			
subjects affected / exposed	1 / 96 (1.04%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
DYSPNOEA			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
EPISTAXIS			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLEURAL EFFUSION			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMOTHORAX			
subjects affected / exposed	0 / 96 (0.00%)	0 / 93 (0.00%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

PULMONARY EMBOLISM			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
ANXIETY			
subjects affected / exposed	0 / 96 (0.00%)	0 / 93 (0.00%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MENTAL STATUS CHANGES			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
BLOOD CREATININE INCREASED			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
EJECTION FRACTION DECREASED			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OXYGEN SATURATION DECREASED			
subjects affected / exposed	0 / 96 (0.00%)	0 / 93 (0.00%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
FEMORAL NECK FRACTURE			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEMUR FRACTURE			

subjects affected / exposed	0 / 96 (0.00%)	0 / 93 (0.00%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PROCEDURAL HYPOTENSION			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RECALL PHENOMENON			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
THORACIC VERTEBRAL FRACTURE			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
ATRIAL FIBRILLATION			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC TAMPONADE			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PERICARDIAL EFFUSION			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TACHYCARDIA			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			



CENTRAL NERVOUS SYSTEM LESION			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HAEMORRHAGE INTRACRANIAL			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEADACHE			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEIZURE			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SYNCOPE			
subjects affected / exposed	1 / 96 (1.04%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VOCAL CORD PARALYSIS			
subjects affected / exposed	0 / 96 (0.00%)	0 / 93 (0.00%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	0 / 96 (0.00%)	2 / 93 (2.15%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEBRILE NEUTROPENIA			
subjects affected / exposed	2 / 96 (2.08%)	7 / 93 (7.53%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	1 / 2	5 / 7	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LYMPHADENOPATHY			

subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEUTROPENIA			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PANCYTOPENIA			
subjects affected / exposed	0 / 96 (0.00%)	0 / 93 (0.00%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
THROMBOCYTOPENIA			
subjects affected / exposed	2 / 96 (2.08%)	2 / 93 (2.15%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	2 / 2	2 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
ABDOMINAL PAIN			
subjects affected / exposed	0 / 96 (0.00%)	3 / 93 (3.23%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	0 / 0	3 / 3	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ABDOMINAL PAIN UPPER			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DIARRHOEA			
subjects affected / exposed	2 / 96 (2.08%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	1 / 2	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NAUSEA			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	0 / 0	2 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VOMITING			

subjects affected / exposed	1 / 96 (1.04%)	1 / 93 (1.08%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	0 / 1	3 / 3	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hepatobiliary disorders</b>			
<b>BILE DUCT OBSTRUCTION</b>			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HEPATOTOXICITY</b>			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Renal and urinary disorders</b>			
<b>URINARY RETENTION</b>			
subjects affected / exposed	0 / 96 (0.00%)	0 / 93 (0.00%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Musculoskeletal and connective tissue disorders</b>			
<b>BONE PAIN</b>			
subjects affected / exposed	0 / 96 (0.00%)	0 / 93 (0.00%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>NECK PAIN</b>			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
<b>PATHOLOGICAL FRACTURE</b>			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
<b>BACTERAEemia</b>			

subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BETA HAEMOLYTIC STREPTOCOCCAL INFECTION			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BREAST CELLULITIS			
subjects affected / exposed	0 / 96 (0.00%)	2 / 93 (2.15%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DEVICE RELATED INFECTION			
subjects affected / exposed	2 / 96 (2.08%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DIVERTICULITIS			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
EMPYEMA			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTROENTERITIS			
subjects affected / exposed	0 / 96 (0.00%)	0 / 93 (0.00%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HERPES ZOSTER			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MASTITIS			

subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OTITIS MEDIA			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA			
subjects affected / exposed	1 / 96 (1.04%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PYELONEPHRITIS			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEPSIS			
subjects affected / exposed	0 / 96 (0.00%)	0 / 93 (0.00%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT INFECTION			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VIRAL UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
DEHYDRATION			
subjects affected / exposed	0 / 96 (0.00%)	0 / 93 (0.00%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPOCALCAEMIA			

subjects affected / exposed	0 / 96 (0.00%)	0 / 93 (0.00%)	1 / 93 (1.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Group 1 Placebo + Carboplatin/ Paclitaxel	Group 1 Veliparib + Carboplatin/ Paclitaxel	Group 1 Veliparib + TMZ
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 2 (100.00%)	1 / 1 (100.00%)	1 / 1 (100.00%)
Vascular disorders			
HAEMATOMA			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
HOT FLUSH			
subjects affected / exposed	1 / 2 (50.00%)	0 / 1 (0.00%)	1 / 1 (100.00%)
occurrences (all)	1	0	1
HYPERTENSION			
subjects affected / exposed	1 / 2 (50.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
ASTHENIA			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
CHILLS			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
FATIGUE			
subjects affected / exposed	1 / 2 (50.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	1	1	0
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
MALAISE			

subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
MUCOSAL INFLAMMATION			
subjects affected / exposed	0 / 2 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	2	0
NON-CARDIAC CHEST PAIN			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
OEDEMA PERIPHERAL			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
PAIN			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
PYREXIA			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
DRUG HYPERSENSITIVITY			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
BREAST PAIN			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
COUGH			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
DYSPNOEA			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
EPISTAXIS			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
OROPHARYNGEAL PAIN			

subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
RHINORRHOEA			
subjects affected / exposed	0 / 2 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
ANXIETY			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
DEPRESSION			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
INSOMNIA			
subjects affected / exposed	0 / 2 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
ASPARTATE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
BLOOD ALKALINE PHOSPHATASE INCREASED			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
BLOOD BILIRUBIN INCREASED			
subjects affected / exposed	0 / 2 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
PLATELET COUNT DECREASED			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
WEIGHT DECREASED			
subjects affected / exposed	1 / 2 (50.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
WEIGHT INCREASED			



subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 1	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Injury, poisoning and procedural complications CONTUSION subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
INFUSION RELATED REACTION subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Cardiac disorders TACHYCARDIA subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 1	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Nervous system disorders DISTURBANCE IN ATTENTION subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 1	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
DIZZINESS subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1
DYSGEUSIA subjects affected / exposed occurrences (all)	2 / 2 (100.00%) 2	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
HEADACHE subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 1	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1
HYPOAESTHESIA subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
LETHARGY subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1
NEUROPATHY PERIPHERAL subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
PARAESTHESIA			

subjects affected / exposed	1 / 2 (50.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
PERIPHERAL SENSORY NEUROPATHY			
subjects affected / exposed	1 / 2 (50.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	1	1	0
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	2 / 2 (100.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	3	5	0
LEUKOPENIA			
subjects affected / exposed	1 / 2 (50.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	2	3	0
LYMPHOPENIA			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
NEUTROPENIA			
subjects affected / exposed	2 / 2 (100.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	13	3	0
THROMBOCYTOPENIA			
subjects affected / exposed	1 / 2 (50.00%)	1 / 1 (100.00%)	1 / 1 (100.00%)
occurrences (all)	1	5	2
Ear and labyrinth disorders			
EAR PAIN			
subjects affected / exposed	1 / 2 (50.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
VERTIGO			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
DRY EYE			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
LACRIMATION INCREASED			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
VISION BLURRED			

subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
ABDOMINAL PAIN			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
ABDOMINAL PAIN UPPER			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
CONSTIPATION			
subjects affected / exposed	0 / 2 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	2	0
DIARRHOEA			
subjects affected / exposed	0 / 2 (0.00%)	1 / 1 (100.00%)	1 / 1 (100.00%)
occurrences (all)	0	1	2
DRY MOUTH			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
DYSPEPSIA			
subjects affected / exposed	1 / 2 (50.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	1	2	0
DYSPHAGIA			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
GASTRITIS			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
GASTROESOPHAGEAL REFLUX DISEASE			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
MELAENA			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	1 / 1 (100.00%)
occurrences (all)	0	0	1
NAUSEA			

subjects affected / exposed	1 / 2 (50.00%)	1 / 1 (100.00%)	1 / 1 (100.00%)
occurrences (all)	1	2	3
STOMATITIS			
subjects affected / exposed	0 / 2 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
TOOTHACHE			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
VOMITING			
subjects affected / exposed	0 / 2 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
ALOPECIA			
subjects affected / exposed	1 / 2 (50.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	1	1	0
DERMATITIS ACNEIFORM			
subjects affected / exposed	1 / 2 (50.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
ERYTHEMA			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
PRURITUS			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
RASH			
subjects affected / exposed	0 / 2 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
URTICARIA			
subjects affected / exposed	1 / 2 (50.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
DYSURIA			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			

ARTHRALGIA			
subjects affected / exposed	1 / 2 (50.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
BACK PAIN			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
BONE PAIN			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
MUSCLE SPASMS			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
MUSCULAR WEAKNESS			
subjects affected / exposed	0 / 2 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
MUSCULOSKELETAL PAIN			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
MYALGIA			
subjects affected / exposed	1 / 2 (50.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
NECK PAIN			
subjects affected / exposed	0 / 2 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
PAIN IN EXTREMITY			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
EAR INFECTION			
subjects affected / exposed	1 / 2 (50.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
GASTROENTERITIS			

subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	1 / 1 (100.00%)
occurrences (all)	0	0	1
INFLUENZA			
subjects affected / exposed	1 / 2 (50.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
NASOPHARYNGITIS			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
SINUSITIS			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
URINARY TRACT INFECTION			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
DEHYDRATION			
subjects affected / exposed	0 / 2 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
HYPERGLYCAEMIA			
subjects affected / exposed	0 / 2 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
HYPOKALAEMIA			
subjects affected / exposed	0 / 2 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	3	0
HYPOMAGNESAEMIA			
subjects affected / exposed	0 / 2 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	2	0

<b>Non-serious adverse events</b>	Group 2 Placebo + Carboplatin/Paclitaxel	Group 2 Veliparib + Carboplatin/Paclitaxel	Group 2 Veliparib + TMZ
-----------------------------------	--	--	-------------------------

Total subjects affected by non-serious adverse events			
subjects affected / exposed	93 / 96 (96.88%)	93 / 93 (100.00%)	91 / 93 (97.85%)
Vascular disorders			
HAEMATOMA			
subjects affected / exposed	5 / 96 (5.21%)	3 / 93 (3.23%)	6 / 93 (6.45%)
occurrences (all)	5	4	10
HOT FLUSH			
subjects affected / exposed	8 / 96 (8.33%)	14 / 93 (15.05%)	11 / 93 (11.83%)
occurrences (all)	12	22	13
HYPERTENSION			
subjects affected / exposed	4 / 96 (4.17%)	2 / 93 (2.15%)	5 / 93 (5.38%)
occurrences (all)	6	2	7
General disorders and administration site conditions			
ASTHENIA			
subjects affected / exposed	15 / 96 (15.63%)	23 / 93 (24.73%)	17 / 93 (18.28%)
occurrences (all)	29	61	59
CHILLS			
subjects affected / exposed	3 / 96 (3.13%)	7 / 93 (7.53%)	2 / 93 (2.15%)
occurrences (all)	3	8	3
FATIGUE			
subjects affected / exposed	57 / 96 (59.38%)	47 / 93 (50.54%)	44 / 93 (47.31%)
occurrences (all)	141	93	76
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	4 / 96 (4.17%)	5 / 93 (5.38%)	3 / 93 (3.23%)
occurrences (all)	5	8	4
MALAISE			
subjects affected / exposed	2 / 96 (2.08%)	3 / 93 (3.23%)	5 / 93 (5.38%)
occurrences (all)	2	4	5
MUCOSAL INFLAMMATION			
subjects affected / exposed	7 / 96 (7.29%)	9 / 93 (9.68%)	3 / 93 (3.23%)
occurrences (all)	10	10	3
NON-CARDIAC CHEST PAIN			
subjects affected / exposed	6 / 96 (6.25%)	6 / 93 (6.45%)	1 / 93 (1.08%)
occurrences (all)	6	6	1
OEDEMA PERIPHERAL			

subjects affected / exposed occurrences (all)	14 / 96 (14.58%) 18	13 / 93 (13.98%) 18	3 / 93 (3.23%) 5
PAIN subjects affected / exposed occurrences (all)	4 / 96 (4.17%) 7	14 / 93 (15.05%) 20	5 / 93 (5.38%) 5
PYREXIA subjects affected / exposed occurrences (all)	18 / 96 (18.75%) 23	15 / 93 (16.13%) 16	9 / 93 (9.68%) 12
Immune system disorders DRUG HYPERSENSITIVITY subjects affected / exposed occurrences (all)	16 / 96 (16.67%) 26	18 / 93 (19.35%) 24	0 / 93 (0.00%) 0
Reproductive system and breast disorders BREAST PAIN subjects affected / exposed occurrences (all)	6 / 96 (6.25%) 6	1 / 93 (1.08%) 1	1 / 93 (1.08%) 1
Respiratory, thoracic and mediastinal disorders COUGH subjects affected / exposed occurrences (all)	15 / 96 (15.63%) 23	21 / 93 (22.58%) 27	13 / 93 (13.98%) 23
DYSPNOEA subjects affected / exposed occurrences (all)	22 / 96 (22.92%) 28	14 / 93 (15.05%) 16	8 / 93 (8.60%) 11
EPISTAXIS subjects affected / exposed occurrences (all)	6 / 96 (6.25%) 7	7 / 93 (7.53%) 8	3 / 93 (3.23%) 8
OROPHARYNGEAL PAIN subjects affected / exposed occurrences (all)	2 / 96 (2.08%) 2	7 / 93 (7.53%) 8	2 / 93 (2.15%) 2
RHINORRHOEA subjects affected / exposed occurrences (all)	3 / 96 (3.13%) 4	8 / 93 (8.60%) 10	3 / 93 (3.23%) 3
Psychiatric disorders ANXIETY subjects affected / exposed occurrences (all)	7 / 96 (7.29%) 7	10 / 93 (10.75%) 13	5 / 93 (5.38%) 9



DEPRESSION			
subjects affected / exposed	6 / 96 (6.25%)	7 / 93 (7.53%)	4 / 93 (4.30%)
occurrences (all)	7	8	4
INSOMNIA			
subjects affected / exposed	23 / 96 (23.96%)	14 / 93 (15.05%)	20 / 93 (21.51%)
occurrences (all)	26	16	21
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	10 / 96 (10.42%)	13 / 93 (13.98%)	6 / 93 (6.45%)
occurrences (all)	17	20	6
ASPARTATE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	10 / 96 (10.42%)	10 / 93 (10.75%)	10 / 93 (10.75%)
occurrences (all)	12	16	12
BLOOD ALKALINE PHOSPHATASE INCREASED			
subjects affected / exposed	1 / 96 (1.04%)	5 / 93 (5.38%)	5 / 93 (5.38%)
occurrences (all)	1	11	5
BLOOD BILIRUBIN INCREASED			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	0 / 93 (0.00%)
occurrences (all)	0	1	0
PLATELET COUNT DECREASED			
subjects affected / exposed	1 / 96 (1.04%)	5 / 93 (5.38%)	1 / 93 (1.08%)
occurrences (all)	1	12	2
WEIGHT DECREASED			
subjects affected / exposed	6 / 96 (6.25%)	4 / 93 (4.30%)	3 / 93 (3.23%)
occurrences (all)	8	5	3
WEIGHT INCREASED			
subjects affected / exposed	4 / 96 (4.17%)	2 / 93 (2.15%)	1 / 93 (1.08%)
occurrences (all)	5	5	1
Injury, poisoning and procedural complications			
CONTUSION			
subjects affected / exposed	4 / 96 (4.17%)	2 / 93 (2.15%)	5 / 93 (5.38%)
occurrences (all)	4	2	5
INFUSION RELATED REACTION			

subjects affected / exposed occurrences (all)	5 / 96 (5.21%) 10	5 / 93 (5.38%) 10	0 / 93 (0.00%) 0
Cardiac disorders TACHYCARDIA subjects affected / exposed occurrences (all)	5 / 96 (5.21%) 6	2 / 93 (2.15%) 2	0 / 93 (0.00%) 0
Nervous system disorders DISTURBANCE IN ATTENTION subjects affected / exposed occurrences (all)	0 / 96 (0.00%) 0	0 / 93 (0.00%) 0	0 / 93 (0.00%) 0
DIZZINESS subjects affected / exposed occurrences (all)	18 / 96 (18.75%) 28	23 / 93 (24.73%) 31	7 / 93 (7.53%) 8
DYSGEUSIA subjects affected / exposed occurrences (all)	12 / 96 (12.50%) 34	18 / 93 (19.35%) 19	12 / 93 (12.90%) 12
HEADACHE subjects affected / exposed occurrences (all)	31 / 96 (32.29%) 41	34 / 93 (36.56%) 61	27 / 93 (29.03%) 50
HYPOAESTHESIA subjects affected / exposed occurrences (all)	6 / 96 (6.25%) 7	4 / 93 (4.30%) 4	2 / 93 (2.15%) 2
LETHARGY subjects affected / exposed occurrences (all)	0 / 96 (0.00%) 0	1 / 93 (1.08%) 1	0 / 93 (0.00%) 0
NEUROPATHY PERIPHERAL subjects affected / exposed occurrences (all)	34 / 96 (35.42%) 64	42 / 93 (45.16%) 60	7 / 93 (7.53%) 7
PARAESTHESIA subjects affected / exposed occurrences (all)	17 / 96 (17.71%) 32	17 / 93 (18.28%) 24	4 / 93 (4.30%) 4
PERIPHERAL SENSORY NEUROPATHY subjects affected / exposed occurrences (all)	22 / 96 (22.92%) 47	31 / 93 (33.33%) 64	4 / 93 (4.30%) 5
Blood and lymphatic system disorders			

ANAEMIA			
subjects affected / exposed	49 / 96 (51.04%)	53 / 93 (56.99%)	26 / 93 (27.96%)
occurrences (all)	113	139	52
LEUKOPENIA			
subjects affected / exposed	27 / 96 (28.13%)	28 / 93 (30.11%)	16 / 93 (17.20%)
occurrences (all)	88	112	55
LYMPHOPENIA			
subjects affected / exposed	4 / 96 (4.17%)	8 / 93 (8.60%)	7 / 93 (7.53%)
occurrences (all)	4	30	8
NEUTROPENIA			
subjects affected / exposed	70 / 96 (72.92%)	68 / 93 (73.12%)	46 / 93 (49.46%)
occurrences (all)	373	402	211
THROMBOCYTOPENIA			
subjects affected / exposed	65 / 96 (67.71%)	66 / 93 (70.97%)	72 / 93 (77.42%)
occurrences (all)	239	312	187
Ear and labyrinth disorders			
EAR PAIN			
subjects affected / exposed	3 / 96 (3.13%)	4 / 93 (4.30%)	3 / 93 (3.23%)
occurrences (all)	8	4	3
VERTIGO			
subjects affected / exposed	5 / 96 (5.21%)	2 / 93 (2.15%)	2 / 93 (2.15%)
occurrences (all)	6	3	2
Eye disorders			
DRY EYE			
subjects affected / exposed	5 / 96 (5.21%)	4 / 93 (4.30%)	4 / 93 (4.30%)
occurrences (all)	6	4	6
LACRIMATION INCREASED			
subjects affected / exposed	5 / 96 (5.21%)	4 / 93 (4.30%)	2 / 93 (2.15%)
occurrences (all)	7	6	2
VISION BLURRED			
subjects affected / exposed	7 / 96 (7.29%)	12 / 93 (12.90%)	1 / 93 (1.08%)
occurrences (all)	7	15	1
Gastrointestinal disorders			
ABDOMINAL PAIN			
subjects affected / exposed	16 / 96 (16.67%)	20 / 93 (21.51%)	15 / 93 (16.13%)
occurrences (all)	19	23	24
ABDOMINAL PAIN UPPER			

subjects affected / exposed	7 / 96 (7.29%)	11 / 93 (11.83%)	7 / 93 (7.53%)
occurrences (all)	14	15	14
CONSTIPATION			
subjects affected / exposed	28 / 96 (29.17%)	38 / 93 (40.86%)	38 / 93 (40.86%)
occurrences (all)	49	57	57
DIARRHOEA			
subjects affected / exposed	25 / 96 (26.04%)	37 / 93 (39.78%)	19 / 93 (20.43%)
occurrences (all)	44	63	27
DRY MOUTH			
subjects affected / exposed	4 / 96 (4.17%)	6 / 93 (6.45%)	8 / 93 (8.60%)
occurrences (all)	4	6	8
DYSPEPSIA			
subjects affected / exposed	15 / 96 (15.63%)	9 / 93 (9.68%)	5 / 93 (5.38%)
occurrences (all)	23	17	5
DYSPHAGIA			
subjects affected / exposed	1 / 96 (1.04%)	2 / 93 (2.15%)	6 / 93 (6.45%)
occurrences (all)	1	2	7
GASTRITIS			
subjects affected / exposed	0 / 96 (0.00%)	5 / 93 (5.38%)	0 / 93 (0.00%)
occurrences (all)	0	5	0
GASTROOESOPHAGEAL REFLUX DISEASE			
subjects affected / exposed	4 / 96 (4.17%)	9 / 93 (9.68%)	4 / 93 (4.30%)
occurrences (all)	4	14	4
MELAENA			
subjects affected / exposed	0 / 96 (0.00%)	1 / 93 (1.08%)	1 / 93 (1.08%)
occurrences (all)	0	1	1
NAUSEA			
subjects affected / exposed	56 / 96 (58.33%)	66 / 93 (70.97%)	69 / 93 (74.19%)
occurrences (all)	133	152	166
STOMATITIS			
subjects affected / exposed	11 / 96 (11.46%)	11 / 93 (11.83%)	5 / 93 (5.38%)
occurrences (all)	20	15	6
TOOTHACHE			
subjects affected / exposed	2 / 96 (2.08%)	5 / 93 (5.38%)	3 / 93 (3.23%)
occurrences (all)	5	5	3

VOMITING subjects affected / exposed occurrences (all)	22 / 96 (22.92%) 36	26 / 93 (27.96%) 41	40 / 93 (43.01%) 81
Skin and subcutaneous tissue disorders			
ALOPECIA subjects affected / exposed occurrences (all)	55 / 96 (57.29%) 69	61 / 93 (65.59%) 79	10 / 93 (10.75%) 13
DERMATITIS ACNEIFORM subjects affected / exposed occurrences (all)	2 / 96 (2.08%) 2	3 / 93 (3.23%) 3	0 / 93 (0.00%) 0
ERYTHEMA subjects affected / exposed occurrences (all)	6 / 96 (6.25%) 7	6 / 93 (6.45%) 7	1 / 93 (1.08%) 1
PRURITUS subjects affected / exposed occurrences (all)	6 / 96 (6.25%) 7	12 / 93 (12.90%) 16	9 / 93 (9.68%) 9
RASH subjects affected / exposed occurrences (all)	17 / 96 (17.71%) 23	7 / 93 (7.53%) 10	5 / 93 (5.38%) 7
URTICARIA subjects affected / exposed occurrences (all)	2 / 96 (2.08%) 2	0 / 93 (0.00%) 0	1 / 93 (1.08%) 1
Renal and urinary disorders			
DYSURIA subjects affected / exposed occurrences (all)	4 / 96 (4.17%) 4	5 / 93 (5.38%) 5	1 / 93 (1.08%) 2
Musculoskeletal and connective tissue disorders			
ARTHRALGIA subjects affected / exposed occurrences (all)	31 / 96 (32.29%) 45	34 / 93 (36.56%) 62	14 / 93 (15.05%) 18
BACK PAIN subjects affected / exposed occurrences (all)	23 / 96 (23.96%) 40	28 / 93 (30.11%) 43	24 / 93 (25.81%) 32
BONE PAIN subjects affected / exposed occurrences (all)	12 / 96 (12.50%) 16	21 / 93 (22.58%) 37	6 / 93 (6.45%) 6

MUSCLE SPASMS			
subjects affected / exposed	9 / 96 (9.38%)	10 / 93 (10.75%)	6 / 93 (6.45%)
occurrences (all)	9	14	6
MUSCULAR WEAKNESS			
subjects affected / exposed	2 / 96 (2.08%)	3 / 93 (3.23%)	1 / 93 (1.08%)
occurrences (all)	3	3	1
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	7 / 96 (7.29%)	4 / 93 (4.30%)	7 / 93 (7.53%)
occurrences (all)	7	5	8
MUSCULOSKELETAL PAIN			
subjects affected / exposed	7 / 96 (7.29%)	14 / 93 (15.05%)	8 / 93 (8.60%)
occurrences (all)	8	16	8
MYALGIA			
subjects affected / exposed	20 / 96 (20.83%)	32 / 93 (34.41%)	8 / 93 (8.60%)
occurrences (all)	38	56	9
NECK PAIN			
subjects affected / exposed	3 / 96 (3.13%)	4 / 93 (4.30%)	2 / 93 (2.15%)
occurrences (all)	4	4	3
PAIN IN EXTREMITY			
subjects affected / exposed	23 / 96 (23.96%)	17 / 93 (18.28%)	13 / 93 (13.98%)
occurrences (all)	39	55	15
Infections and infestations			
EAR INFECTION			
subjects affected / exposed	1 / 96 (1.04%)	0 / 93 (0.00%)	0 / 93 (0.00%)
occurrences (all)	1	0	0
GASTROENTERITIS			
subjects affected / exposed	1 / 96 (1.04%)	4 / 93 (4.30%)	2 / 93 (2.15%)
occurrences (all)	1	4	2
INFLUENZA			
subjects affected / exposed	3 / 96 (3.13%)	3 / 93 (3.23%)	4 / 93 (4.30%)
occurrences (all)	5	4	4
NASOPHARYNGITIS			
subjects affected / exposed	12 / 96 (12.50%)	12 / 93 (12.90%)	5 / 93 (5.38%)
occurrences (all)	13	18	5
SINUSITIS			

subjects affected / exposed occurrences (all)	7 / 96 (7.29%) 7	5 / 93 (5.38%) 6	1 / 93 (1.08%) 1
UPPER RESPIRATORY TRACT INFECTION subjects affected / exposed occurrences (all)	10 / 96 (10.42%) 11	20 / 93 (21.51%) 28	14 / 93 (15.05%) 17
URINARY TRACT INFECTION subjects affected / exposed occurrences (all)	9 / 96 (9.38%) 14	12 / 93 (12.90%) 13	13 / 93 (13.98%) 13
Metabolism and nutrition disorders			
DECREASED APPETITE subjects affected / exposed occurrences (all)	20 / 96 (20.83%) 27	22 / 93 (23.66%) 30	21 / 93 (22.58%) 29
DEHYDRATION subjects affected / exposed occurrences (all)	0 / 96 (0.00%) 0	3 / 93 (3.23%) 3	0 / 93 (0.00%) 0
HYPERGLYCAEMIA subjects affected / exposed occurrences (all)	5 / 96 (5.21%) 7	3 / 93 (3.23%) 4	1 / 93 (1.08%) 1
HYPOKALAEMIA subjects affected / exposed occurrences (all)	6 / 96 (6.25%) 7	9 / 93 (9.68%) 12	1 / 93 (1.08%) 1
HYPOMAGNESAEMIA subjects affected / exposed occurrences (all)	11 / 96 (11.46%) 18	17 / 93 (18.28%) 21	2 / 93 (2.15%) 2

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 March 2012	Modified the dose of veliparib/placebo to 120 mg BID for subjects randomized to the C/P treatment arms as the recommended Phase 2 dose based on the currently available data from the Cancer Treatment Evaluation Program 7967 and GOG 9923 studies.
28 January 2013	Allowed for broader eligibility while maintaining patient characteristics consistent with the trial intent and modified secondary efficacy endpoints and clarified definition of CBR to include all intent-to-treat (ITT) subjects and ORR to include only subjects with at least 1 measurable lesion at baseline.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported